tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX

7.829USD

-0.001-0.01%
Horarios del mercado ETCotizaciones retrasadas 15 min
2.45BCap. mercado
PérdidaP/E TTM

Amneal Pharmaceuticals Inc

7.829

-0.001-0.01%
Más Datos de Amneal Pharmaceuticals Inc Compañía
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Información de la empresa
Símbolo de cotizaciónAMRX
Nombre de la empresaAmneal Pharmaceuticals Inc
Fecha de salida a bolsaNov 18, 2009
Director ejecutivoMr. Chintu Patel
Número de empleados8100
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 18
Dirección400 Crossing Boulevard, 3rd Floor
CiudadBRIDGEWATER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal08807
Teléfono19089473120
Sitio Webhttps://amneal.com/
Símbolo de cotizaciónAMRX
Fecha de salida a bolsaNov 18, 2009
Director ejecutivoMr. Chintu Patel
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
+1.39%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
433.93K
-10.17%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
+1.39%
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
433.93K
-10.17%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Oral solid
178.95M
25.73%
Distribution
104.89M
15.08%
Central Nervous System
67.61M
9.72%
Other dosage forms
56.42M
8.11%
Government label
50.14M
7.21%
Other
237.40M
34.14%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Oral solid
178.95M
25.73%
Distribution
104.89M
15.08%
Central Nervous System
67.61M
9.72%
Other dosage forms
56.42M
8.11%
Government label
50.14M
7.21%
Other
237.40M
34.14%
Estadísticas de accionistas
Actualizado: jue., 22 de may
Actualizado: jue., 22 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Patel (Tushar Bhikhubhai)
15.50%
Patel (Chintu)
8.17%
Patel (Dipan)
7.60%
Patel (Chirag K)
7.06%
Akram (Mahesh)
6.56%
Other
55.10%
Accionistas
Accionistas
Proporción
Patel (Tushar Bhikhubhai)
15.50%
Patel (Chintu)
8.17%
Patel (Dipan)
7.60%
Patel (Chirag K)
7.06%
Akram (Mahesh)
6.56%
Other
55.10%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
46.67%
Investment Advisor
16.20%
Hedge Fund
11.70%
Investment Advisor/Hedge Fund
10.50%
Private Equity
3.93%
Research Firm
0.97%
Pension Fund
0.26%
Bank and Trust
0.17%
Venture Capital
0.03%
Other
9.56%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
429
283.55M
90.47%
-32.20M
2025Q1
437
285.44M
91.08%
-30.39M
2024Q4
413
285.94M
92.29%
-32.70M
2024Q3
398
304.85M
98.50%
-8.45M
2024Q2
391
304.30M
98.56%
+52.65M
2024Q1
375
272.60M
88.40%
+17.73M
2023Q4
366
275.21M
90.82%
+129.07M
2023Q3
354
120.75M
78.38%
-3.68M
2023Q2
353
115.91M
75.59%
-7.89M
2023Q1
359
114.33M
74.58%
-11.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Patel (Tushar Bhikhubhai)
48.58M
15.5%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.17%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.06%
+345.41K
+1.59%
Mar 14, 2025
Akram (Mahesh)
20.56M
6.56%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
15.71M
5.01%
+920.76K
+6.23%
Mar 31, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.14M
3.55%
-80.92K
-0.72%
Mar 31, 2025
Rubric Capital Management LP
10.74M
3.43%
+14.20K
+0.13%
Mar 31, 2025
Citadel Advisors LLC
7.49M
2.39%
-1.49M
-16.58%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Pharmaceuticals ETF
3%
SPDR S&P Pharmaceuticals ETF
2.22%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.57%
AltShares Event-Driven ETF
1.53%
First Trust NASDAQ Pharmaceuticals ETF
0.87%
iShares U.S. Pharmaceuticals ETF
0.61%
First Trust Small Cap Growth AlphaDEX Fund
0.53%
First Trust Small Cap Core Alphadex Fund
0.29%
Invesco Nasdaq Biotechnology ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.28%
Ver más
Invesco Pharmaceuticals ETF
Proporción3%
SPDR S&P Pharmaceuticals ETF
Proporción2.22%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.57%
AltShares Event-Driven ETF
Proporción1.53%
First Trust NASDAQ Pharmaceuticals ETF
Proporción0.87%
iShares U.S. Pharmaceuticals ETF
Proporción0.61%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.53%
First Trust Small Cap Core Alphadex Fund
Proporción0.29%
Invesco Nasdaq Biotechnology ETF
Proporción0.28%
ProShares Ultra Nasdaq Biotechnology
Proporción0.28%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI